Sidhartha Tan

Prof. Dr. Sidhartha Tan

Children's Hospital of Michigan
+1

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
JVJeannette Vasquez-Vivar
Jeannette Vasquez-Vivar
ZSZhongjie Shi
Zhongjie Shi
STSidhartha Tan
Sidhartha Tan
Significance: Tetrahydrobiopterin (BH4) is most well known as a required cofactor for enzymes regulating cellular redox homeostasis, aromatic amino acid metabolism, and neurotransmitter synthesis. Less well known are the effects dependent on the cofactor's availability, factors governing its synthesis and recycling, redox implications of the cofactor itself, and protein–protein interactions that underlie cell death. This review provides an understanding of the recent advances implicating BH4 in the mechanisms of cell death and suggestions of possible therapeutic interventions. Recent Advances: The levels of BH4 often reflect the sum of synthetic and recycling enzyme activities. Enhanced expression of GTP cyclohydrolase, the rate-limiting enzyme in biosynthesis, increases BH4, leading to improved cell function and survival. Pharmacologically increasing BH4 levels has similar beneficial effects, leading to enhanced production of neurotransmitters and nitric oxide or reducing oxidant levels. The GTP cyclohydrolase-BH4 pairing has been implicated in a type of cell death, ferroptosis. At the cellular level, BH4 counteracts anticancer therapies directed to enhance ferroptosis via glutathione peroxidase 4 (GPX4) activity inhibition. Critical Issues: Because of the multitude of intertwined mechanisms, a clear relationship between BH4 and cell death is not well understood yet. The possibility that the cofactor directly influences cell viability has not been excluded in previous studies when modulating BH4-producing enzymes. Future Directions: The importance of cellular BH4 variations and BH4 biosynthetic enzymes to cell function and viability makes it essential to better characterize temporal changes, cofactor activity, and the influence on redox status, which in turn would help develop novel therapies. Antioxid. Redox Signal . 37, 171–183.

12 March 2024 in Chemistry – A European Journal
Verified
Journal Article
Closed access
NANuwandi M. Ariyasingha
Nuwandi M. Ariyasingha
RCRaduanul H. Chowdhury
Raduanul H. Chowdhury
ASAnna Samoilenko
Anna Samoilenko
OSOleg G. Salnikov
Oleg G. Salnikov
NCNikita V. Chukanov
Nikita V. Chukanov
ECEduard Y Chekmenev
Eduard Y Chekmenev

1 October 2017 in Redox Biology
Verified
Journal Article
Open access
JVJeannette Vasquez-Vivar
Jeannette Vasquez-Vivar
ZSZhongjie Shi
Zhongjie Shi
KLKehuan Luo
Kehuan Luo
KTKarthikeyan Thirugnanam
Karthikeyan Thirugnanam
STSidhartha Tan
Sidhartha Tan
Antenatal brain hypoxia-ischemia, which occurs in cerebral palsy, is considered a significant cause of motor impairments in children. The mechanisms by which antenatal hypoxia-ischemia causes brain injury and motor deficits still need to be elucidated. Tetrahydrobiopterin is an important enzyme cofactor that is necessary to produce neurotransmitters and to maintain the redox status of the brain. A genetic deficiency of this cofactor from mutations of biosynthetic or recycling enzymes is a well-recognized factor in the development of childhood neurological disorders characterized by motor impairments, developmental delay, and encephalopathy. Experimental hypoxia-ischemia causes a decline in the availability of tetrahydrobiopterin in the immature brain. This decline coincides with the loss of brain function, suggesting this occurrence contributes to neuronal dysfunction and motor impairments. One possible mechanism linking tetrahydrobiopterin deficiency, hypoxia-ischemia, and neuronal injury is oxidative injury. Evidence of the central role of the developmental biology of tetrahydrobiopterin in response to hypoxic ischemic brain injury, especially the development of motor deficits, is discussed.

31 December 2010 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
LYLei Yu
Lei Yu
ADAlexander Drobyshevsky
Alexander Drobyshevsky
MDMatthew Derrick
Matthew Derrick
KLKehuan Luo
Kehuan Luo
IBInes Batinic-Haberle
Ines Batinic-Haberle
STSidhartha Tan
Sidhartha Tan

30 September 2022 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
STSidhartha Tan
Sidhartha Tan
ZSZhongjie Shi
Zhongjie Shi

30 October 2019
Verified
Dataset
Closed access
STSidhartha Tan
Sidhartha Tan
SJSanket Jani
Sanket Jani
This is a groundbreaking research paper in which an individualized milasen, a splice-modulating antisense oligonucleotide, was created to treat a single patient suffering from Batten disease, which is a progressive neurodegenerating disease, and using a template from a previous drug, nusinersen, to treat spinal muscular atrophy. The authors worked on an aggressive timeline not only to create a drug for that individual patient, but they were able to test the drug on fibroblast cells derived from the patient, receive regulatory approval from the FDA and get the commercially manufactured drug within 14 months. The treatment has helped the patient to resolve or decrease many of her symptoms. It is a feat that has rarely been achieved before. In one sense, this process serves as a template for overcoming what seems like a herculean task in clinical drug development but in another sense, one wonders about a future where drug development is biased towards diseases affecting people with resources and money.